Stay updated on Nivolumab for Hematologic Malignancies Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Hematologic Malignancies Clinical Trial page.

Latest updates to the Nivolumab for Hematologic Malignancies Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.5.0 added and Revision: v3.4.3 removed.SummaryDifference0.1%

- Check10 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a minor backend/UI release with no visible changes to study data or navigation.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedAdded site revision note 'Revision: v3.4.2' and removed a funding-status notice; these are minor metadata changes that do not affect the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check45 days agoChange DetectedA site-wide notice about government funding lapse and NIH Clinical Center status was added, and the site version updated to v3.4.1 (replacing v3.4.0). These changes do not modify the study details, enrollment, endpoints, or eligibility for the NCT03146468 study.SummaryDifference0.5%

- Check52 days agoChange DetectedUI updates include a new 'Show glossary' option, a revision stamp (v3.4.0), and added notices such as 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check66 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4; no changes to the study details, layout, or user-facing content were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nivolumab for Hematologic Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Hematologic Malignancies Clinical Trial page.